RAPT RAPT Therapeutics
WatchlistRAPT Therapeutics News
JP Morgan Maintains Overweight on RAPT Therapeutics, Raises Price Target to $35
JP Morgan analyst Anupam Rama maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and raises the price target from $32 to $35.
RAPT Therapeutics(RAPT.US) Officer Sells US$20,580 in Common Stocks
$RAPT Therapeutics(RAPT.US)$ Officer HO WILLIAM sold 1,500 shares of Common Stocks on Nov 28, 2023 at an average price of $13.72 for a total value of $20,580.Source: Announcement What is statement of
Buy Rating on RAPT Therapeutics Backed by Promising Phase 1a/1b Study Results for Atopic Dermatitis Drug RPT193
RAPT Therapeutics Announces Publication Of Phase 1a/1b Clinical Trial of Zelnecirnon To Treat Atopic Dermatitis In Allergy
Positive clinical and molecular effects observed, with improvements demonstrated in key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at four weeksFurther d
HC Wainwright & Co. Reiterates Buy on RAPT Therapeutics, Maintains $41 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:RAPT) with a Buy and maintains $41 price target.
RAPT Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/15/2023 209.2% HC Wainwright & Co. → $41 Reiterates Buy → Buy 09/14/2023 156.41% Berenberg → $34 Initia
Analysts' Top Healthcare Picks: Mustang Bio (MBIO), RAPT Therapeutics (RAPT)
Piper Sandler Keeps Their Buy Rating on RAPT Therapeutics (RAPT)
Yanan Zhu Recommends 'Buy' for RAPT Therapeutics: Positive Clinical Trials and Financial Stability Predict Potential Value Increase
Recap: RAPT Therapeutics Q3 Earnings
RAPT Therapeutics (NASDAQ:RAPT) reported its Q3 earnings results on Monday, November 13, 2023 at 08:00 AM.Here's what investors need to know about the announcement.EarningsRAPT Therapeutics missed est
RAPT Therapeutics Q3 EPS $(0.82) Misses $(0.75) Estimate
RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.82) per share which missed the analyst consensus estimate of $(0.75) by 9.33 percent. This is a 30.16 percent decrease over losses of $
Promising Clinical Data and Potential Partnerships Bolster Buy Rating Recommendation for RAPT Therapeutics
Piper Sandler Reaffirms Their Buy Rating on RAPT Therapeutics (RAPT)
Promising Clinical Trial Results Bolster Buy Rating for RAPT Therapeutics: A Detailed Analysis
J.P. Morgan Remains a Buy on RAPT Therapeutics (RAPT)
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, From Its Phase 2 Trial of FLX475 in Combination With a Checkpoint Inhibitor in Patients With Advanced NSCLC
- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI)- Median progression-free survival (PFS) of 6.3 months in PD-L1 po
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and
RAPT Therapeutics Insiders Lose Out As Stock Sinks To US$12.24
The recent price decline of 20% in RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) stock may have disappointed insiders who bought US$97.6k worth of shares at an average price of US$19.52 in the past 12 month
RAPT Therapeutics(RAPT.US) Officer Sells US$39,425 in Common Stocks
$RAPT Therapeutics(RAPT.US)$ Officer HO WILLIAM sold 2,500 shares of Common Stocks on Oct 3, 2023 at an average price of $15.77 for a total value of $39,425.Source: Announcement What is statement of c